OXSORALEN LOT 10MG/ML LOTION

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

METHOXSALEN

Disponible depuis:

VALEANT CANADA LP / VALEANT CANADA S.E.C.

Code ATC:

D05AD02

DCI (Dénomination commune internationale):

METHOXALEN, TOPICAL

Dosage:

10MG

forme pharmaceutique:

LOTION

Composition:

METHOXSALEN 10MG

Mode d'administration:

TOPICAL

Unités en paquet:

30ML

Type d'ordonnance:

Prescription

Domaine thérapeutique:

PIGMENTING AGENTS

Descriptif du produit:

Active ingredient group (AIG) number: 0107802001; AHFS:

Statut de autorisation:

CANCELLED POST MARKET

Date de l'autorisation:

2015-08-05

Résumé des caractéristiques du produit

1
PRESCRIBING INFORMATION
OXSORALEN
Lotion 1%
(Methoxsalen, USP)
Melanin Repigmentation
Photochemotherapy of Psoriasis and Atopic
Dermatitis
Valeant Canada LP
2150 St-Elzear Blvd., West
Laval, Quebec
H7L 4A8
Canada
Date of Preparation: September 27, 2004
Address Updated: September 04, 2014
Control#: 094181
2
PRESCRIBING INFORMATION
OXSORALEN Lotion 1%
(methoxsalen, USP)
Melanin repigmentation
Photochemotherapy of Psoriasis and Atopic Dermatitis
INDICATIONS
Repigmentation of vitiliginous lesions and treatment of psoriasis and
atopic dermatitis in
combination with high intensity UVA light. Oral route is preferred if
extensive repigmentation
is desired since topical application can only be applied to a small
area at a time.
CONTRAINDICATIONS
Oxsoralen Lotion 1% is contraindicated in patients exhibiting
idiosyncratic reactions to psoralens
or with a history of a sensitivity reaction to the drug; in patients
with diseases associated with
photosensitivity
(e.g.,
lupus
erythematosus,
porphyria
cutanea
tarda,
erythropoietic
protoprophyria, varietate porphyria, xeroderma pigmentosum, albinism,
hydroa vacciniforme,
leukoderma
of
infectious
origin,
polymorphous
light
eruptions),
except
under
special
circumstances; in patients with melanoma or history of melanoma; and
in patients with invasive
squamous cell carcinoma.
Safety in patients 12 years and under, in aphasic people, in pregnant
women or in women of
childbearing age has not been established. No preparation with any
photosensitizing capacity,
internal or external, should be used concomitantly with methoxsalen
therapy.
3
WARNINGS
Methoxsalen is a potent drug capable of producing severe burns if
improperly used. Oxsoralen
Lotion should be applied ONLY by a physician under controlled
conditions as to light exposure
and subsequent light shielding.
OXSORALEN LOTION 1% SHOULD NEVER BE DISPENSED TO A
PATIENT FOR HOME APPLICATION.
Oxsoralen
Lotion
1%
should
be
applied
only
to
small,
well-defined
vitiliginous
lesions,
preferably those lesions that can be protected by clothing